F8 and hemophilia A: This prevented the establishment of a clear relationship between replacement strategy and perioperative bleeding risk and hindered the evaluation of the comparative effectiveness of hemostatic protocols in the setting of cardiac surgery in patients with hemophilia A. Considering the publication dates of the included cases and the availability of extended half-life (EHL) factor VIII (FVIII) products on the market, it is reasonable to assume that most cases involved the use of standard half-life (SHL) FVIII concentrates, since EHL concentrates were only introduced starting in 2014.